Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

The interaction of Q analogs, particularly hydroxydecyl benzoquinone (idebenone), with the respiratory complexes of heart mitochondria.
Copolymer-1 promotes neurogenesis and improves functional recovery after acute ischemic stroke in rats.
Determination and characterization of a cannabinoid receptor in rat brain.
Efficacy and safety study of RPC1063 in relapsing multiple sclerosis patients
Tcelna® (imilecleucel-T)
Development of cladribine at Scripps for hairy cell leukemia and current results.
Immunomodulatory therapeutic effect of glatiramer acetate on several murine models of inflammatory bowel disease.
Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre.
Enhancement of axonal potassium conductance reduces nerve hyperexcitability in an in vitro model of oxaliplatin-induced acute neuropathy.
Zebrafish myelination: a transparent model for remyelination?
Current and future disease-modifying therapies in multiple sclerosis.
Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis.
Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone.
Genzyme’s once-daily, oral AUBAGIO® approved in Australia for treatment of relapsing multiple sclerosis
Phase 4 GI Tolerability Study of DMF in Patients With Relapsing Forms of MS in the US (MANAGE)
Biogen Third Quarter 2015 Revenues Increase 11% to $2.8 Billion; Company Raises 2015 Full Year Guidance
Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis.
Withdrawal of the marketing authorization in the European Union
Use of amiloride and multiple sclerosis: registry-based cohort studies.
Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.
Effect of Natalizumab on Circulating CD4(+) T-Cells in Multiple Sclerosis.
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
Alemtuzumab
Safety Study of Interferon Beta-1a for Acute Stroke
Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis.

Pages